General description
We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency".
Click here for more information.
ZooMAb® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb® antibodies are reliably available and ready to ship when you need them.
Specificity
Clone 1D20 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects Interleukin-8 (IL-8). It targets an epitope within 21 amino acids from the C-terminal region.
Immunogen
KLH-conjugated linear peptide corresponding to 21 amino acids from the C-terminal region of human Interleukin-8 (IL-8).
Application
Quality Control Testing
Evaluated by Western Blotting with a recombinant fragment of Human IL-8
Western Blotting Analysis: A 1:10,000 dilution of this antibody detected a recombinant fragment corresponding to 72 amino acids from the C-terminal region of Human IL-8.
Tested Applications
Flow Cytometry Analysis: 1 µg from a representative lot detected IL-8 in one million Human peripheral blood mononuclear cells (PBMC).
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected IL-8 in Human tonsil tissue sections.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Target description
Interleukin-8 (UniProt: P10145; also known as IL-8, C-X-C motif chemokine 8, Chemokine (C-X-C motif) ligand 8 Emoctakin, Granulocyte chemotactic protein 1, GCP-1, Monocyte-derived neutrophil chemotactic factor, MDNCF, Monocyte-derived neutrophil-activating peptide, MONAP, Neutrophil-activating protein 1, NAP-1, Protein 3-10C, T-cell chemotactic factor) is encoded by the CXCL8 (also known as IL8) gene (Gene ID: 3576) in human. IL-8 is a homodimeric protein that is synthesized with a signal peptide (aa 1-20), which is subsequently cleaved off to produce the mature protein. Several N-terminal processed forms of IL-8 are produced by proteolytic cleavage after secretion from peripheral blood monocytes, leukocytes, and endothelial cells. IL-8 (aa 6-77) is the most prominent form. IL-8 is a proinflammatory cytokine that serves as a chemotactic factor that attracts neutrophils, basophils, and T-cells during the inflammatory process. It is involved in neutrophil activation and attracts neutrophils to sites of inflammation and plays an important role in host defense against bacterial infections. It is released in response to an inflammatory stimulus and exerts its effect by binding to the G-protein-coupled receptors CXCR1 and CXCR2 that are primarily found in neutrophils, monocytes, and endothelial cells. Citrullination of IL-8 on arginine 27 prevents proteolysis and dampens tissue inflammation and also enhances leukocytosis, possibly through impaired chemokine clearance from the blood circulation. IL-8 is reported to promote cell migration via CXCR1 and CXCR2 in liver cancer. Higher levels of CXCR1, CXCR2, and IL-8 are associated with advanced tumor stage and increased risk of lymph node or distant metastasis. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonal. (Ref.: Bi, H., et al. (2019). Oncol. Lett. 18(4); 4176-4184; Proost, P., et al. (2008). J. Exp. Med. 205(9); 2085-2097; Hammond, ME., et al. (1995). J. Immunol. 155(3); 1428-1433).
Physical form
Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
Reconstitution
300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Storage and Stability
Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
Legal Information
ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.